OncoMatch/Clinical Trials/NCT03896568
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Is NCT03896568 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Oncolytic Adenovirus Ad5-DNX-2401 for idh1 wt allele.
Treatment: Oncolytic Adenovirus Ad5-DNX-2401 — This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
Required: IDH1 wild-type
Prior therapy
Must have received: surgical resection, biopsy, chemotherapy or radiation
Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan after failing prior surgical resection, biopsy, chemotherapy or radiation
Cannot have received: biologic/immunotherapy
Biologic/immunotherapy within 2 weeks of baseline
Lab requirements
Blood counts
absolute granulocyte count > 1,500 and platelet count of > 75,000
Kidney function
creatinine < 2.0 times institutional normal
Liver function
sgpt and sgot and bilirubin < 2 times institutional normal ranges
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify